News articles about Clementia Pharmaceuticals (NASDAQ:CMTA) have been trending somewhat positive on Friday, according to Accern Sentiment Analysis. The research group ranks the sentiment of press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Clementia Pharmaceuticals earned a coverage optimism score of 0.01 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 45.9383880875563 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
CMTA has been the subject of several recent research reports. B. Riley initiated coverage on Clementia Pharmaceuticals in a research note on Wednesday, March 28th. They issued a “buy” rating and a $25.00 price target for the company. Zacks Investment Research upgraded Clementia Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, March 20th. Finally, ValuEngine upgraded Clementia Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $26.60.
CMTA opened at $13.74 on Friday. Clementia Pharmaceuticals has a 1 year low of $11.72 and a 1 year high of $20.15. The firm has a market capitalization of $443.73 million and a P/E ratio of -1.73.
Clementia Pharmaceuticals (NASDAQ:CMTA) last posted its quarterly earnings data on Wednesday, May 9th. The company reported ($0.42) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.33) by ($0.09). equities analysts predict that Clementia Pharmaceuticals will post -1.77 earnings per share for the current fiscal year.
Clementia Pharmaceuticals Company Profile
Clementia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, develops treatments for patients suffering from bone disorders and other diseases. Its lead product candidate is palovarotene, an oral small molecule for the treatment of fibrodysplasia ossificans progressive, multiple osteochondromas, dry eye disease, and other diseases is in the Phase 3 MOVE Trial.
Receive News & Ratings for Clementia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clementia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.